FDA Places Lead MS Drug (Lucid-MS) IND on Clinical Hold, Halting Development
QNTM has more than doubled off its 52-week low of $2.07.
Summary
Quantum Biopharma's lead multiple sclerosis drug candidate, Lucid-MS, has been placed on clinical hold by the FDA, delaying its development and forcing the company to withdraw all previous timelines.
Key Events · Product Development and Regulatory · QNTM
-
FDA Clinical Hold on Lucid-MS IND
The U.S. Food and Drug Administration (FDA) has placed the Investigational New Drug (IND) application for Lucid-MS, the company's lead drug candidate for multiple sclerosis, on clinical hold as of May 28, 2026. The company is reviewing the FDA's comments and intends to submit a response, believing the issues are addressable.
-
Withdrawal of Development Timelines
Quantum Biopharma is withdrawing all previously disclosed timelines related to FDA review, initiation of the planned Phase 2 trial, and anticipated interim data milestones for Lucid-MS, indicating a significant delay in the program.
-
Director Resignation
Dr. Lakshmi P. Kotra has resigned as a director and from all positions at Quantum Biopharma and its subsidiaries, effective June 1, 2026, citing personal and professional commitments. He will remain as a senior clinical advisor.
Analysis · QNTM · Life Sciences
The FDA has placed Quantum Biopharma's Investigational New Drug (IND) application for Lucid-MS, its lead multiple sclerosis drug candidate, on clinical hold. This is a significant setback, directly impacting the company's development timeline and introducing substantial uncertainty for a program previously highlighted as a major positive. The company has withdrawn all previously disclosed timelines for FDA review, Phase 2 trial initiation, and interim data milestones, underscoring the severity of the delay. While the company believes the issues are addressable, resolving a clinical hold can be a lengthy process. The simultaneous resignation of a director, even with a stated reason, adds to the negative sentiment.
At the time of this filing, QNTM was trading at $4.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29M. The 52-week trading range was $2.07 to $38.25. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.